Invention Grant
- Patent Title: Substituted imidazo[1,5-a]pyrazines for IRE1 inhibition
-
Application No.: US16642208Application Date: 2018-08-31
-
Publication No.: US11649237B2Publication Date: 2023-05-16
- Inventor: Richard M. Keenan , Bradley J. Backes , Dustin J. Maly , Charles Reynolds , Ben Whittaker , Jamie Knight , Jonathan Mark Sutton , George Hynd , Feroz R. Papa , Scott A. Oakes
- Applicant: Optikira LLC , The Regents of the University of California
- Applicant Address: US OH Cleveland
- Assignee: Optikira LLC,The Regents of the University of California
- Current Assignee: Optikira LLC,The Regents of the University of California
- Current Assignee Address: US OH Cleveland; US CA Oakland
- Agency: Saul Ewing LLP
- International Application: PCT/US2018/049081 2018.08.31
- International Announcement: WO2019/046711A 2019.03.07
- Date entered country: 2020-02-26
- Main IPC: A61K31/4985
- IPC: A61K31/4985 ; C07D487/04 ; C07D519/00
![Substituted imidazo[1,5-a]pyrazines for IRE1 inhibition](/abs-image/US/2023/05/16/US11649237B2/abs.jpg.150x150.jpg)
Abstract:
Provided herein, inter alia, are substituted imidazo[1,5-α]pyrazine compounds, compositions and methods for treating or preventing an IRE1α-related disease or disorder. In certain embodiments, the disease or disorder is selected from the group consisting of a neurodegenerative disease, a demyelinating disease, cancer, an eye disease, a fibrotic disease, and diabetes.
Information query
IPC分类: